Exabis Library
Welcome to the e-CCO Library!
P386: Anti-TNF alpha as induction and maintenance therapy in ulcerative colitis patients in the BioColitis Registry in Germany
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P386: Association of Infliximab trough levels and perianal disease activity in Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P386: Clinical presentation, management, and evolution of lymphomas in patients with Inflammatory Bowel Disease: an ENEIDA registry study.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P386: Methotrexate use in combination with anti-TNFα agents in IBD: A tertiary centre experience
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P386: Predictive models for assessing the response to ustekinumab in Crohn’s disease patients
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P386: Two year follow up of children with Inflammatory Bowel Disease (IBD) treated with vedolizumab and ustekinumab
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P387 Real-world clinical outcomes of biologic-naïve non-complicated Crohn’s disease patients treated with vedolizumab: Results from the EVOLVE study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P387: Depression in biologic-treated patients with inflammatory bowel disease during the COVID19 pandemic
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P387: Different rate of transmural remission between first and second line of biologic treatment in Crohn's disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P387: Does standard therapy in paediatric Crohn’s disease really prevent our patients from the need of early initiation of anti-TNF treatment?
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P387: Efficacy of combination therapy of fresh faecal microbiota transplantation and triple-antibiotic therapy for ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P387: Infliximab therapeutic drug monitoring test validated for measuring CT-P13 and SB2 biosimilars
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P387: Rapid Implementation of an Evidence-Based, Virtual COVID-19 Vaccine Education Clinic at the Nova Scotia Collaborative Inflammatory Bowel Disease Clinic (NSCIBD) Program
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P387: The addition of an immunosuppressant is an effective optimization strategy after loss of response to anti-TNF-alpha monotherapy in patients with inflammatory bowel disease: a two-year experience
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P388 Prediction model to safely CEASE anti-TNF therapy in Crohn’s disease: validation of a predictive diagnostic tool for the cessation of anti-TNF treatment in CD in a Dutch population
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P388: Agreement between locally and centrally reviewed Mayo endoscopic subscores in the UNIFI study of ustekinumab in patients with Ulcerative Colitis
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P388: Analysis of the impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis programme
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P388: Asking teenagers and young adults with IBD; “what matters to you?”. A qualitative survey during the COVID-19 pandemic
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P388: Clinical care pathways are needed to decrease variability in the management of the hospitalised ulcerative colitis patient
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P388: Response to IV steroid therapy in acute severe ulcerative colitis (ASUC) is not altered by admission to a tertiary referral centre: The NHS Lothian experience
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM